

IMPORTANT DOSING INFORMATION

LUNSUMIO® (mosunetuzumab-axgb) and LUNSUMIO VELO™ (mosunetuzumab-axgb) have different dosage and administration instructions

- LUNSUMIO is for intravenous use only and LUNSUMIO VELO is for subcutaneous use only
- Check the product label to ensure that the correct formulation is being prescribed and administered
- Do not substitute LUNSUMIO for or with LUNSUMIO VELO and vice versa

LUNSUMIO (mosunetuzumab-axgb) ¹	Indication	LUNSUMIO VELO (mosunetuzumab-axgb) ²
3L+ Follicular Lymphoma		3L+ Follicular Lymphoma
Intravenous infusion	Route of Administration	Subcutaneous injection
Cycle 1 Day 1: 1 mg Cycle 1 Day 8: 2 mg Cycle 1 Day 15: 60 mg Cycle 2 Day 1: 60 mg Cycle 3+ Day 1: 30 mg	Recommended Dose and Schedule	Cycle 1 Day 1: 5 mg Cycle 1 Day 8: 45 mg Cycle 1 Day 15: 45 mg Cycle 2+ Day 1: 45 mg
8 cycles for patients who achieve a CR* 17 cycles for patients who achieve a PR or SD*	Treatment Duration	8 cycles for patients who achieve a CR* 17 cycles for patients who achieve a PR or SD*
1 mg/mL single-dose vial (NDC 50242-159-01) 30 mg/30 mL (1 mg/mL) single-dose (NDC 50242-142-01)	How Supplied	5 mg/0.5 mL single-dose vial (NDC 50242-177-01) 45 mg/mL single-dose vial (NDC 50242-201-01)
NDC 50242-159-01 Lunsumio® (mosunetuzumab-axgb) Injection 1 mg/mL For Intravenous Infusion Only. Single-Dose Vial. Discard Unused Portion. Genentech, Inc. U.S. Lic. No.: 1048 NDC 50242-142-01 Lunsumio® (mosunetuzumab-axgb) Injection 30 mg/30 mL (1 mg/mL) For Intravenous Infusion Only. Single-Dose Vial. Discard Unused Portion. Genentech, Inc. U.S. Lic. No.: 1048	Vial Labels	NDC 50242-177-01 Lunsumio Velo™ (mosunetuzumab-axgb) Injection 5 mg/0.5 mL For Subcutaneous Use Only. Single-Dose Vial. Discard Unused Portion. Genentech, Inc. U.S. Lic. No.: 1048 NDC 50242-201-01 Lunsumio Velo™ (mosunetuzumab-axgb) Injection 45 mg/mL For Subcutaneous Use Only. Single-Dose Vial. Discard Unused Portion. Genentech, Inc. U.S. Lic. No.: 1048
⚠ Do not use in-line filter Lunsumio® 11029402 US	Peel-off Label	5 mg Subcutaneous Lunsumio Velo™ 11027623 US 45 mg Subcutaneous Lunsumio Velo™ 11028150 US
	Vials	

Images are illustrative and do not reflect actual size, scale, or proportions.
*Unless patients experience unacceptable toxicity or disease progression.
3L+=third line and beyond; CR= complete response; PR=partial response; SD=stable disease.
References: 1. LUNSUMIO [prescribing information](#). Genentech, Inc.; 2025. 2. LUNSUMIO VELO [prescribing information](#). Genentech, Inc.; 2025.
This is a medical resource for scientific information and is intended for healthcare providers practicing in the United States.